HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Jean-François Chatal Selected Research

Carcinoembryonic Antigen

8/2012Phase II trial of anticarcinoembryonic antigen pretargeted radioimmunotherapy in progressive metastatic medullary thyroid carcinoma: biomarker response and survival improvement.
4/2006Survival improvement in patients with medullary thyroid carcinoma who undergo pretargeted anti-carcinoembryonic-antigen radioimmunotherapy: a collaborative study with the French Endocrine Tumor Group.
2/2006Antibody pretargeting advances cancer radioimmunodetection and radioimmunotherapy.
2/2006Targeting, toxicity, and efficacy of 2-step, pretargeted radioimmunotherapy using a chimeric bispecific antibody and 131I-labeled bivalent hapten in a phase I optimization clinical trial.
11/2005Prognostic impact of serum calcitonin and carcinoembryonic antigen doubling-times in patients with medullary thyroid carcinoma.
9/2003Pharmacokinetics and dosimetry studies for optimization of anti-carcinoembryonic antigen x anti-hapten bispecific antibody-mediated pretargeting of Iodine-131-labeled hapten in a phase I radioimmunotherapy trial.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Jean-François Chatal Research Topics

Disease

18Neoplasms (Cancer)
02/2015 - 02/2002
7Thyroid Neoplasms (Thyroid Cancer)
08/2014 - 05/2005
4medullary Thyroid cancer
06/2012 - 02/2002
4Non-Hodgkin Lymphoma (Lymphosarcoma)
12/2009 - 12/2003
3Lymphoma (Lymphomas)
01/2012 - 11/2006
2Hematologic Diseases (Blood Diseases)
02/2015 - 01/2012
2Multiple Myeloma
08/2008 - 04/2007
2Neoplasm Metastasis (Metastasis)
11/2005 - 08/2005
1Brain Neoplasms (Brain Tumor)
08/2008
1Neuroendocrine Tumors (Neuroendocrine Tumor)
08/2008
1Leukemia
08/2008
1Follicular Lymphoma (Lymphoma, Small Cleaved Cell, Follicular)
07/2008
1Hodgkin Disease (Hodgkin's Disease)
11/2006
1Lung Neoplasms (Lung Cancer)
02/2006
1Glioma (Gliomas)
02/2006
1Carcinoid Tumor (Carcinoid)
08/2005
1Hematologic Neoplasms (Hematological Malignancy)
05/2002

Drug/Important Bio-Agent (IBA)

7AntibodiesIBA
02/2015 - 05/2002
7Radioisotopes (Radionuclides)IBA
02/2015 - 05/2002
6HaptensIBA
01/2015 - 02/2002
6Carcinoembryonic AntigenIBA
08/2012 - 09/2003
5Calcitonin (Calcitonin, Eel)FDA LinkGeneric
08/2012 - 02/2002
4AntigensIBA
01/2015 - 02/2002
3Bispecific AntibodiesIBA
01/2015 - 05/2002
3Peptides (Polypeptides)IBA
06/2012 - 05/2002
3AcidsIBA
02/2006 - 02/2002
2Biotin (Vitamin H)FDA Link
01/2015 - 02/2006
2Biomarkers (Surrogate Marker)IBA
08/2014 - 08/2012
2Monoclonal AntibodiesIBA
06/2012 - 05/2005
2Pentetic Acid (DTPA)FDA LinkGeneric
02/2006 - 02/2002
2IndiumIBA
02/2006 - 02/2002
1Iodine-124IBA
02/2015
1Lutetium-177IBA
02/2015
1Bismuth-213IBA
02/2015
1Astatine-211IBA
02/2015
1Actinium-225IBA
02/2015
1Fluorine-18IBA
02/2015
1Copper-64IBA
02/2015
1Copper-67IBA
02/2015
1Gallium-68IBA
02/2015
1Zirconium-89IBA
02/2015
1AvidinIBA
01/2015
1Immunoconjugates (Immunoconjugate)IBA
01/2015
1vandetanib (ZD6474)IBA
06/2012
1Protons (Proton)IBA
08/2008
1Somatostatin (Somatotropin Release-Inhibiting Factor)IBA
08/2008
1GemcitabineFDA Link
04/2007
1Deoxyglucose (2 Deoxy D glucose)IBA
11/2006
1StreptavidinIBA
02/2006
1DNA (Deoxyribonucleic Acid)IBA
09/2005
1RadiopharmaceuticalsIBA
08/2005
1epratuzumabIBA
12/2003
11,4,7,10-tetraazacyclododecane- 1,4,7,10-tetraacetic acidIBA
12/2003
1Immunoglobulin G (IgG)IBA
12/2003
1Surface Antigens (Surface Antigen)IBA
05/2002
1Doxorubicin (Adriamycin)FDA LinkGeneric
02/2002
1Paclitaxel (Taxol)FDA LinkGeneric
02/2002

Therapy/Procedure

15Radioimmunotherapy
01/2015 - 02/2002
10Therapeutics
02/2015 - 02/2002
2Radiotherapy
08/2008 - 08/2005
1Precision Medicine
02/2015
1Drug Therapy (Chemotherapy)
11/2006
1Secondary Prevention
11/2006
1Aftercare (After-Treatment)
02/2002